Isalia Sans Sucre Édulcoré À L’aspartam (Metopimazine)

Metopimazine acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone of the brain. By blocking these receptors, it reduces the neural signals that trigger the vomiting reflex, thereby providing symptomatic relief from nausea and vomiting.

The appropriate dose of Metopimazine is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and response to therapy. Dosing instructions are individualized and should be followed as directed by the prescriber.

Safety data for Metopimazine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metopimazine belongs to the phenothiazine class, differing from serotonin antagonists like ondansetron. It primarily blocks dopamine receptors, which can be advantageous in cases where dopaminergic pathways dominate the emetic response. Choice of antiemetic depends on the clinical scenario and patient tolerance.

Metopimazine oral tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Metopimazine is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise instructed by a healthcare professional.

Serious risks include extrapyramidal symptoms such as muscle rigidity or tremor, neuroleptic malignant syndrome, severe hypotension, and cardiac arrhythmias. Patients should be monitored for these events, and therapy should be discontinued if they occur.

Metopimazine is contraindicated in individuals with known hypersensitivity to phenothiazines or any component of the formulation. Caution is also advised for patients with severe cardiac disease, uncontrolled hypertension, or a history of neuroleptic malignant syndrome.